WO2008152537A3 - Humanized monoclonal antibodies - Google Patents
Humanized monoclonal antibodies Download PDFInfo
- Publication number
- WO2008152537A3 WO2008152537A3 PCT/IB2008/052038 IB2008052038W WO2008152537A3 WO 2008152537 A3 WO2008152537 A3 WO 2008152537A3 IB 2008052038 W IB2008052038 W IB 2008052038W WO 2008152537 A3 WO2008152537 A3 WO 2008152537A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- monoclonal antibodies
- mabs
- humanized
- humanized monoclonal
- studies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Humanized MAbs are designed, created and produced using a series of innovative processes comprising of computational analysis, modeling studies, rationale assessment and selection of humanized sequences, an efficient recombinant DNA expression system and functional studies to interrogate the therapeutic properties of the MAbs. The invention also provides an economic and scalable process of producing the monoclonal antibodies in large quantities and find use in the treatment of human diseases like cancer. Also described is a panel of novel humanized MAbs directed against the human EGFR that acts as receptor antagonists and are substantially non-immunogenic.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1236CH2007 | 2007-06-14 | ||
IN1236/CHE/2007 | 2007-06-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008152537A2 WO2008152537A2 (en) | 2008-12-18 |
WO2008152537A3 true WO2008152537A3 (en) | 2010-04-08 |
Family
ID=40130263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2008/052038 WO2008152537A2 (en) | 2007-06-14 | 2008-05-23 | Humanized monoclonal antibodies against human epidermal growth factor receptor, use and method thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008152537A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
NZ630020A (en) | 2012-03-08 | 2016-08-26 | Halozyme Inc | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
KR20160055253A (en) | 2013-09-12 | 2016-05-17 | 할로자임, 아이엔씨 | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6114146A (en) * | 1994-11-14 | 2000-09-05 | Baxter Aktiengesellschaft | Expression plasmid, a fusion protein, a transfected eukaryotic cell line, a method of producing foreign proteins, a foreign protein preparation as well as a pharmaceutical composition |
US6602684B1 (en) * | 1998-04-20 | 2003-08-05 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
-
2008
- 2008-05-23 WO PCT/IB2008/052038 patent/WO2008152537A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6114146A (en) * | 1994-11-14 | 2000-09-05 | Baxter Aktiengesellschaft | Expression plasmid, a fusion protein, a transfected eukaryotic cell line, a method of producing foreign proteins, a foreign protein preparation as well as a pharmaceutical composition |
US6602684B1 (en) * | 1998-04-20 | 2003-08-05 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
Non-Patent Citations (1)
Title |
---|
ROGUSKA ET AL.: "Humanization of murine monoclonal antibodies through variable domain resurfacing", PNAS, vol. 91, 1994, pages 969 - 973, XP002271704, DOI: doi:10.1073/pnas.91.3.969 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008152537A2 (en) | 2008-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL301196I2 (en) | inebilizumab | |
WO2007044756A3 (en) | Monoclonal antibodies recognizing human ccr8 | |
PH12015500782A1 (en) | Human cytomegalovirus neutralizing antibodies and use thereof | |
TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
WO2006099875A8 (en) | Antibodies against cd38 for treatment of multiple myeloma | |
WO2009083009A3 (en) | Monoclonal antibodies against cd32b | |
WO2011147982A3 (en) | Monoclonal antibodies against her2 epitope | |
WO2010129033A3 (en) | Modified antibodies for passive immunotherapy | |
NZ610734A (en) | Human antibodies to the glucagon receptor | |
EP3539988A3 (en) | Monoclonal antibodies against her2 | |
WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
NZ591471A (en) | Antibodies to ccr2 | |
MX2010009190A (en) | HUMANIZED ANTI-C5aR ANTIBODIES. | |
TN2010000210A1 (en) | Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same | |
WO2005103081A3 (en) | Human monoclonal antibodies against cd20 | |
MX355181B (en) | Human antibodies against human tissue factor. | |
WO2006089133A8 (en) | Anti-cd19 antibodies and uses in oncology | |
MY157173A (en) | Modified humanised anti-interleukin-18 | |
WO2011143624A3 (en) | Humanized and chimeric monoclonal antibodies to cd47 | |
DOP2009000221A (en) | UNION PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, WHICH SPECIFICALLY JOIN CD154 AND ITS USES | |
WO2011044311A3 (en) | Generation, characterization and uses thereof of anti-her 3 antibodies | |
WO2010072740A3 (en) | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF | |
WO2008152537A3 (en) | Humanized monoclonal antibodies | |
PH12020551012A1 (en) | Monoclonal antibodies and methods for using same | |
WO2008042941A3 (en) | Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08751313 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08751313 Country of ref document: EP Kind code of ref document: A2 |